rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

James P. Moran

Director

Company insider

Files Form 4 as: Director, IGC Pharma.

In numbers

Trades disclosed
36
Buys
1
Sells
0
Bought
$200K
Sold
$0
Companies
1
Companies where not an officer
1
First trade
18 Jan 2022
Last trade
1 Apr 2026
Last filed
6 Apr 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
IGC IGC PharmaDirector · Biotechnology · last 1 Apr 20261 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
101Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
1 Apr 2026filed 6 Apr 2026IGC IGC PharmaBiotechnologySEC FORM 4 Code M—80,000 at $0.00filing
1 Apr 2026filed 6 Apr 2026IGC IGC PharmaBiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
1 Apr 2026filed 6 Apr 2026IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—80,000 at $0.00filing
1 Apr 2026filed 6 Apr 2026IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—80,000 at $0.00filing
1 Apr 2026filed 6 Apr 2026IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
1 Apr 2026filed 6 Apr 2026IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
1 Apr 2026filed 6 Apr 2026IGC IGC PharmaBiotechnologySEC FORM 4 Code M—80,000 at $0.00filing
1 Apr 2026filed 6 Apr 2026IGC IGC PharmaBiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
17 Oct 2025filed 21 Oct 2025IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code A—500,000 at $0.00filing
31 Mar 2025filed 15 May 2025IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—33,333 at $0.00filing
31 Mar 2025filed 15 May 2025IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—80,000 at $0.00filing
31 Mar 2025filed 15 May 2025IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
31 Mar 2025filed 15 May 2025IGC IGC PharmaBiotechnologySEC FORM 4 Code M—33,333 at $0.00filing
31 Mar 2025filed 15 May 2025IGC IGC PharmaBiotechnologySEC FORM 4 Code M—80,000 at $0.00filing
31 Mar 2025filed 15 May 2025IGC IGC PharmaBiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
25 Sep 2024filed 27 Sep 2024IGC IGC PharmaBiotechnologySEC FORM 4 Bought$200K588,235 at $0.34filing
13 Mar 2024filed 15 Mar 2024IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—33,333 at $0.00filing
13 Mar 2024filed 15 Mar 2024IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—50,000 at $0.00filing
13 Mar 2024filed 15 Mar 2024IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—80,000 at $0.00filing
13 Mar 2024filed 15 Mar 2024IGC IGC Pharmaoption or derivative · BiotechnologySEC FORM 4 Code M—57,500 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Health Care1

Buys in green, sells in red, by the company’s sector.

Related people

Ram MukundaCEO · CEO at IGC Pharma, filing Form 4 there in the last year
Claudia GrimaldiPfo · Pfo at IGC Pharma, filing Form 4 there in the last year
Richard K. PrinsDirector · Director at IGC Pharma, filing Form 4 there in the last year